Vaccine goal indicators

in page functions
[French]

To accelerate equitable uptake and coverage of vaccines

Routine immunisation coverage

What we measure: the percentage of children reached with the third dose of pentavalent vaccine, which protects against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b, and the first dose of measles vaccine in Gavi-supported countries.

Universally present in the routine schedules of Gavi-supported countries, coverage estimates for these two vaccines provide a reliable indicator of the proportion of children with access to basic immunisation services.


Breadth of protection

What we measure: the percentage of children reached with the last dose of seven vaccines recommended across all Gavi-supported countries and the last dose of three vaccines specific to certain regions.a 


Equity: geographic distribution

What we measure: the average percentage of districts across the countries we support in which coverage with a third dose of pentavalent vaccine is equal to or greater than 80%.


Equity: wealth distribution

What we measure: the average difference in coverage with a third dose of pentavalent vaccine between the poorest fifth of the population and the richest 20% across the Gavi-supported countries where recent data is available. Due to the low availability of data, measuring progress in this area remains a challenge.


Equity: maternal education

What we measure: the average difference in coverage between children of non-educated mothers or other female caregivers, and those whose mothers have at least completed secondary school. We use three doses of pentavalent vaccine as the basis for this indicator, which includes all Gavi-supported countries where recent data is available. However, the lack of availability of data poses challenges for accurately tracking this indicator.


a In 2017, this indicator only tracked six vaccines. Human papillomavirus vaccine was not included due to lack of data.

 

82%

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 0.88 in 2017, and is expected to decrease further to US$ 0.79 by 2019.

Gavi 2018

More facts...

close icon

modal window here